Caseware UK (AP4) 2023.0.135 2023.0.135 2024-06-302024-06-30falsefalse182023-07-01Manufacture of medical and dental instruments and supplies15falsetrue 09796975 2023-07-01 2024-06-30 09796975 2024-06-30 09796975 2022-07-01 2023-06-30 09796975 2023-06-30 09796975 c:Director1 2023-07-01 2024-06-30 09796975 c:Director2 2023-07-01 2024-06-30 09796975 c:Director3 2023-07-01 2024-06-30 09796975 c:Director4 2023-07-01 2024-06-30 09796975 c:Director5 2023-07-01 2024-06-30 09796975 c:Director6 2023-07-01 2024-06-30 09796975 c:Director7 2023-07-01 2024-06-30 09796975 c:Director7 2024-06-30 09796975 c:RegisteredOffice 2023-07-01 2024-06-30 09796975 d:Buildings d:LongLeaseholdAssets 2023-07-01 2024-06-30 09796975 d:Buildings d:LongLeaseholdAssets 2024-06-30 09796975 d:Buildings d:LongLeaseholdAssets 2023-06-30 09796975 d:PlantMachinery 2023-07-01 2024-06-30 09796975 d:PlantMachinery 2024-06-30 09796975 d:PlantMachinery 2023-06-30 09796975 d:PlantMachinery d:OwnedOrFreeholdAssets 2023-07-01 2024-06-30 09796975 d:OfficeEquipment 2023-07-01 2024-06-30 09796975 d:OfficeEquipment 2024-06-30 09796975 d:OfficeEquipment 2023-06-30 09796975 d:OfficeEquipment d:OwnedOrFreeholdAssets 2023-07-01 2024-06-30 09796975 d:ComputerEquipment 2023-07-01 2024-06-30 09796975 d:ComputerEquipment 2024-06-30 09796975 d:ComputerEquipment 2023-06-30 09796975 d:ComputerEquipment d:OwnedOrFreeholdAssets 2023-07-01 2024-06-30 09796975 d:OtherPropertyPlantEquipment 2023-07-01 2024-06-30 09796975 d:OtherPropertyPlantEquipment 2024-06-30 09796975 d:OtherPropertyPlantEquipment 2023-06-30 09796975 d:OtherPropertyPlantEquipment d:OwnedOrFreeholdAssets 2023-07-01 2024-06-30 09796975 d:OwnedOrFreeholdAssets 2023-07-01 2024-06-30 09796975 d:PatentsTrademarksLicencesConcessionsSimilar 2024-06-30 09796975 d:PatentsTrademarksLicencesConcessionsSimilar 2023-06-30 09796975 d:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-06-30 09796975 d:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-06-30 09796975 d:CopyrightsPatentsTrademarksServiceOperatingRights 2024-06-30 09796975 d:CopyrightsPatentsTrademarksServiceOperatingRights 2023-06-30 09796975 d:CurrentFinancialInstruments 2024-06-30 09796975 d:CurrentFinancialInstruments 2023-06-30 09796975 d:CurrentFinancialInstruments d:WithinOneYear 2024-06-30 09796975 d:CurrentFinancialInstruments d:WithinOneYear 2023-06-30 09796975 d:ShareCapital 2024-06-30 09796975 d:ShareCapital 2023-06-30 09796975 d:SharePremium 2024-06-30 09796975 d:SharePremium 2023-06-30 09796975 d:RetainedEarningsAccumulatedLosses 2024-06-30 09796975 d:RetainedEarningsAccumulatedLosses 2023-06-30 09796975 d:FurtherSpecificTypeProvisionContingentLiability1ComponentTotalProvisionsContingentLiabilities 2023-06-30 09796975 c:FRS102 2023-07-01 2024-06-30 09796975 c:Audited 2023-07-01 2024-06-30 09796975 c:FullAccounts 2023-07-01 2024-06-30 09796975 c:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 09796975 c:SmallCompaniesRegimeForAccounts 2023-07-01 2024-06-30 09796975 2 2023-07-01 2024-06-30 09796975 d:PatentsTrademarksLicencesConcessionsSimilar d:OwnedIntangibleAssets 2023-07-01 2024-06-30 09796975 d:DevelopmentCostsCapitalisedDevelopmentExpenditure d:OwnedIntangibleAssets 2023-07-01 2024-06-30 09796975 d:CopyrightsPatentsTrademarksServiceOperatingRights d:OwnedIntangibleAssets 2023-07-01 2024-06-30 09796975 e:PoundSterling 2023-07-01 2024-06-30 iso4217:GBP xbrli:pure
Company registration number: 09796975







FINANCIAL STATEMENTS
FOR THE YEAR ENDED
30 JUNE 2024


ORTHOSON LIMITED






































img6a4b.png                        

 


ORTHOSON LIMITED
 


 
COMPANY INFORMATION


Directors
Professor C C Coussios 
R E Simmonds 
G O Edwards 
J H C Mallinson 
Dr N C Birch 
A-T Doxiadis 
K M Reali (appointed 17 October 2023)




Registered number
09796975



Registered office
The Magdalen Centre
Robert Robinson Avenue

Oxford

Oxfordshire

OX4 4GA




Independent auditors
Menzies LLP
Chartered Accountants & Statutory Auditor

1st Floor

Midas House

62 Goldsworth Road

Woking

Surrey

GU21 6LQ





 


ORTHOSON LIMITED
 



CONTENTS



Page
Statement of financial position
1 - 2
Notes to the financial statements
3 - 9

 


ORTHOSON LIMITED
REGISTERED NUMBER:09796975



STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2024

2024
2023
Note
£
£

Fixed assets
  

Intangible assets
 4 
40,325
52,101

Tangible assets
 5 
164,863
294,054

  
205,188
346,155

Current assets
  

Debtors: amounts falling due within one year
 6 
489,408
870,859

Bank and cash balances
  
2,150,948
4,337,927

  
2,640,356
5,208,786

Creditors: amounts falling due within one year
 7 
(132,978)
(234,170)

Net current assets
  
 
 
2,507,378
 
 
4,974,616

Total assets less current liabilities
  
2,712,566
5,320,771

Provisions for liabilities
  

Provisions
 8 
(30,000)
(30,000)

  
 
 
(30,000)
 
 
(30,000)

Net assets
  
2,682,566
5,290,771


Capital and reserves
  

Called up share capital 
  
4,202
4,061

Share premium account
  
11,472,147
11,472,147

Profit and loss account
  
(8,793,783)
(6,185,437)

  
2,682,566
5,290,771

Page 1

 


ORTHOSON LIMITED
REGISTERED NUMBER:09796975


    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 30 JUNE 2024

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




................................................
R E Simmonds
Director

Date: 22 January 2025

The notes on pages 3 to 9 form part of these financial statements.

Page 2

 


ORTHOSON LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

1.


General information

OrthoSon Limited is a private company limited by shares, incorporated in the United Kingdom under the Companies Act 2006, registered in England and Wales.

The address of its registered office is disclosed on the company information page. The principal place of business is the same as the registered office.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

  
2.2

Licence option

During the period ended 30 June 2016, the Company capitalised an option to license or assign certain pieces of intellectual property in the field of orthopaedic surgery on the basis that it is likely to be of significant use to the business for the foreseeable future. Amortisation of the option to licence will begin, on a 25% declining balance basis, once commercialisation of the technology has begun.

 
2.3

Going concern

The financial statements have been prepared on a going concern basis, which assumes that the Company will continue in operation for the foreseeable future.
There was a loss for the year of £2,608,346 (2023: £2,490,297) and at the year end the company had cash of £2,150,948 (2023: £4,337,927).
The company will require further funding for its ongoing R&D program and future clinical trials and is planning a fundraise to complete in Q1 2025.
Taking into account current cash balances, the expected net proceeds from a fundraise and the expected costs over the going concern assessment period, the Directors have prepared the financial forecast for the going concern assessment period, which shows that there is sufficient cash runway to cover the entire period.
Whilst the Directors are confident that the fundraise will be successfully completed, until such time as binding funding commitments are received, the ability to secure necessary funding represents a material uncertainty that may cast significant doubt on the company’s ability to continue as a going concern and, therefore, to continue realising its assets and discharging its liabilities in the normal course of business. These financial statements do not contain any adjustments that would arise if the financial statements were not prepared on a going concern basis.

Page 3

 


ORTHOSON LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

2.Accounting policies (continued)

 
2.4

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

 
2.5

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

 
2.6

Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

 
2.7

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.8

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of financial position. The assets of the plan are held separately from the Company in independently administered funds.

Page 4

 


ORTHOSON LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

2.Accounting policies (continued)

 
2.9

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.
 
 
2.10

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

Development costs are an intangible asset already being used to contribute to the development of the company's technology. The Company amortises on a 25% declining balance basis. 

 
2.11

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Long-term leasehold property
-
Over life of lease
Plant and machinery
-
33%
Office equipment
-
33%
Computer equipment
-
33%
Lab Equipment
-
33%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.12

Impairment of fixed assets

Assets that are subject to depreciation or amortisation are assessed at each reporting date to determine whether there is any indication that the assets are impaired. Where there is any indication that an asset may be impaired, the carrying value of the asset is tested for impairment. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows.

Page 5

 


ORTHOSON LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

2.Accounting policies (continued)

 
2.13

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.
Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.
 
 
2.14

Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.


3.


Employees

The average monthly number of employees, including directors, during the year was 18 (2023 - 15).


4.


Intangible assets




Patents
Development expenditure
Licence option
Total

£
£
£
£



Cost


At 1 July 2023
125,100
68,750
5,000
198,850



At 30 June 2024

125,100
68,750
5,000
198,850



Amortisation


At 1 July 2023
94,313
52,436
-
146,749


Charge for the year on owned assets
7,697
4,079
-
11,776



At 30 June 2024

102,010
56,515
-
158,525



Net book value



At 30 June 2024
23,090
12,235
5,000
40,325



At 30 June 2023
30,787
16,314
5,000
52,101



Page 6

 


ORTHOSON LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

5.


Tangible fixed assets





Long-term leasehold property
Plant and machinery
Office equipment
Computer equipment
Lab Equipment
Total

£
£
£
£
£
£



Cost or valuation


At 1 July 2023
208,674
143,927
13,102
75,660
719,621
1,160,984


Additions
25,764
-
-
3,863
87,058
116,685


Disposals
-
(66,745)
(719)
(3,491)
(101,403)
(172,358)



At 30 June 2024

234,438
77,182
12,383
76,032
705,276
1,105,311



Depreciation


At 1 July 2023
187,496
143,919
11,730
67,228
456,557
866,930


Charge for the year on owned assets
34,060
8
1,372
7,460
161,766
204,666


Disposals
-
(66,745)
(719)
(3,467)
(96,063)
(166,994)


Impairment charge
-
-
-
-
35,846
35,846



At 30 June 2024

221,556
77,182
12,383
71,221
558,106
940,448



Net book value



At 30 June 2024
12,882
-
-
4,811
147,170
164,863



At 30 June 2023
21,178
8
1,372
8,432
263,064
294,054

Page 7

 


ORTHOSON LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

6.


Debtors

2024
2023
£
£


Other debtors
81,720
69,023

Prepayments and accrued income
42,466
24,610

Tax recoverable
365,222
777,226

489,408
870,859



7.


Creditors: Amounts falling due within one year

2024
2023
£
£

Trade creditors
35,165
170,499

Other taxation and social security
33,334
2,616

Other creditors
8,686
6,243

Accruals and deferred income
55,793
54,812

132,978
234,170



8.


Provisions





Dilapidation provision

£





At 1 July 2023 and 30 June 2024
30,000


9.


Pension commitments

The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the company to the fund and amounted to £52,438 (2023 - £46,282). Contributions totalling £8,143 were payable (2023) - £3,843 were repayable) to the fund at the balance sheet date and are included in creditors.


10.


Related party transactions

During the year the company paid remuneration to three (2023: three) directors as a sole trader, Ltd company and LLP.
A director invoiced as a sole trader £158,181 (2023: £60,000)
A director was invoiced from an LLP £6,750 (2023: £6,750)
A director was invoiced from a Ltd company £87,979 (2023: £57,383)

Page 8

 


ORTHOSON LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

11.


Auditors' information

The auditors' report on the financial statements for the year ended 30 June 2024 was unqualified.

The audit report was signed on 22 January 2025 by Miriam Hanley ACA (Senior statutory auditor) on behalf of Menzies LLP.

 
Page 9